Sorrento Therapeutics skyrockets 244% after claiming a breakthrough on COVID-19 drug
an antibody it's developing showed 100% inhibition of the COVID-19 virus in preclinical studies.
Sorrento said it will ask regulators for priority evaluation and an accelerated review of its drug candidate.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Stephen Colbert Tackles Trump's Attempts to Undermine Whistleblower Rick BrightStephen Colbert highlighted whistleblower Rick Bright's chilling testimony about COVID-19 — and Trump's attempts to undermine him
Weiterlesen »
Asia-Pacific drug trade thrives amid the COVID-19 pandemicIllicit drug markets in the Asia-Pacific continue to expand and diversify and appear to be largely unaffected by the coronavirus outbreak, the United Nations said on Friday.
Weiterlesen »
Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivirTwo health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus patients around the world, particularly in poorer nations.
Weiterlesen »
Vince McMahon Claims XFL Commish 'Abandoned' Job After COVID-19 BeganVince McMahon claims ex-XFL commissioner Oliver Luck 'abandoned' his duties when the COVID-19 pandemic broke out in March ... and that's one of the main reasons Vince fired him, according to court documents.
Weiterlesen »
U.S. SEC charges two companies, CEO over misleading COVID-19 claimsThe U.S. Securities and Exchange Commission said on Thursday it has charged two companies and a chief executive officer with making misleading claims related to COVID-19, the disease caused by the novel coronavirus.
Weiterlesen »
'Vogue' and Amazon Fashion Partner on Digital Storefront for 'A Common Thread'It's part of the effort to support American designers amid the Covid-19 pandemic.
Weiterlesen »